Boston, MA -- (SBWIRE) -- 07/03/2013 -- GlobalData has released its new PharmaPoint Drug Evaluation report, "Gleevec (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022". Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients' survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.

View Full Report Details and Table of Contents

Novartis' Gleevec (imatinib mesylate) was the first BCR-ABL TKI approved for CML. Gleevec was first approved in the US and the 5EU in 2001 for Ph+ CML patients in blast phase, accelerated phase, or chronic phase after they had failed IFN-a therapy, with approval as a first-line therapy in newly diagnosed CP-CML patients following shortly thereafter, in 2002 (Gleevec Prescribing Information, 2012). In Japan, Gleevec was initially approved for all CML patients in 2001, with no prerequisite for prior therapy with IFN-a (Initial Patient Target Achieved for Glivec within 3 Months, 2002). Gleevec's approval completely changed the competitive landscape of CML, quickly replacing older therapies like IFN-a to become the gold-standard first-line treatment for adults and children with CML.

Scope

- Overview of CML, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Gleevec including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Gleevec for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to Get This Report

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for CML
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Gleevec performance
- Obtain sales forecast for Gleevec from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- PharmaPoint: Chronic Myeloid Leukemia (CML) - Japan Drug Forecast and Market Analysis to 2022
- PharmaPoint: Chronic Myeloid Leukemia (CML) - Germany Drug Forecast and Market Analysis to 2022
- PharmaPoint: Chronic Myeloid Leukemia (CML) - Italy Drug Forecast and Market Analysis to 2022
- PharmaPoint: Chronic Myeloid Leukemia (CML) - France Drug Forecast and Market Analysis to 2022
- PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022
- PharmaPoint: Chronic Myeloid Leukemia (CML) - United States Drug Forecast and Market Analysis to 2022
- PharmaPoint: Chronic Myeloid Leukemia (CML) - Spain Drug Forecast and Market Analysis to 2022
- Bosulif (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022
- Tasigna (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022
- EpiCast Report: Chronic Myeloid Leukemia - Epidemiology Forecast to 2022